EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

Romiplostim with ciclosporin A in patients with aplastic anaemia naïve to immunosuppressive therapy: A phase 2/3 study

Jong Wook Lee, Jun Ho Jang iD, Shigeru Chiba iD, Sung-Soo Yoon, Gaku Oshikawa, Kensuke Usuki, Yeung-Chul Mun, Toshiro Kawakita, Kazunori Imada, June-Won Cheong, Masayoshi Noshiro, Akira Matsuda und 4 weitere

British Journal of Haematology · 2025

DOI: 10.1111/bjh.20206 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Jong Wook Lee und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Hanyang University Seoul Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Anemia, Aplastic, Recombinant Fusion Proteins, Cyclosporine, Thrombopoietin. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Kyowa Kirin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Romiplostim has been shown to restore multi‐lineage haematopoiesis and is effective in patients with aplastic anaemia (AA) refractory to immunosuppressive therapy (IST). This open‐label, phase 2/3 study (NCT04095936) recruited adult AA patients in Japan and Korea who had not received prior IST and evaluated the efficacy and safety of romiplostim plus ciclosporin A (CsA). Romiplostim was initiated at 10 μg/kg once weekly through Week 4 and adjusted between 0 and 20 μg/kg from Week 5 onwards. CsA was administered at 5–6 mg/kg/day in two divided doses through Week 26. A total of 24 patients (median [range] age, 52 [19–80] years) were enrolled, and 22 (91.7%) completed the study. Four patients (16.7%) had very severe AA (VSAA), 13 (54.2%) had severe AA (SAA) and seven (29.2%) had transfusion‐dependent non‐severe AA (NSAA). A haematological response at Week 27 was observed in 10/24 patients (overall response, 41.7%; 95% confidence interval, 22.1%–63.4%). At Week 27, the subgroup overall response rates were 0.0% in VSAA, 46.2% in SAA and 57.1% in NSAA. Nearly 92% of patients experienced at least one treatment‐emergent adverse event (TEAE), but no drug‐related Grade ≥3 TEAEs were reported. One patient developed myelodysplastic syndromes. Treatment with romiplostim plus CsA was effective and well tolerated in patients with AA who had not previously received IST.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, AplasticRecombinant Fusion ProteinsCyclosporineThrombopoietinReceptors, FcImmunosuppressive AgentsHumansMiddle AgedAdultMaleFemaleAgedAged, 80 and overYoung AdultDrug Therapy, CombinationTreatment Outcome

Stichwörter der Autor:innen

aplastic anaemiaciclosporinimmunosuppressive therapyromiplostimthrombopoietin

Substanzen

romiplostimRecombinant Fusion ProteinsCyclosporineThrombopoietinReceptors, FcImmunosuppressive Agents

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Hanyang University Seoul Hospital, Seoul, Republic of Korea.
  • Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Department of Hematology, University of Tsukuba, Tsukuba, Japan.
  • Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
  • Department of Hematology, Japan Red Cross Musashino Hospital Tokyo, Tokyo, Japan.
  • Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan.

ORCID-Profile: Jun Ho Jang, Shigeru Chiba, Shinji Nakao

Förderung

  • Kyowa Kirin

Zitieren

APA

Lee, J. W., Jang, J. H., Chiba, S., Yoon, S. S., Oshikawa, G., Usuki, K., Mun, Y. C., Kawakita, T., Imada, K., Cheong, J. W., Noshiro, M., Matsuda, A., Ozawa, K., Mitani, K., Kanda, Y., & Nakao, S. (2025). Romiplostim with ciclosporin A in patients with aplastic anaemia naïve to immunosuppressive therapy: A phase 2/3 study. British Journal of Haematology. https://doi.org/10.1111/bjh.20206

Vancouver

Lee JW, Jang JH, Chiba S, Yoon SS, Oshikawa G, Usuki K, et al. Romiplostim with ciclosporin A in patients with aplastic anaemia naïve to immunosuppressive therapy: A phase 2/3 study. British Journal of Haematology. 2025. doi:10.1111/bjh.20206

BibTeX
@article{Lee2025,
  author = {Lee, Jong Wook and Jang, Jun Ho and Chiba, Shigeru and Yoon, Sung-Soo and Oshikawa, Gaku and Usuki, Kensuke and Mun, Yeung-Chul and Kawakita, Toshiro and Imada, Kazunori and Cheong, June-Won and Noshiro, Masayoshi and Matsuda, Akira and Ozawa, Keiya and Mitani, Kinuko and Kanda, Yoshinobu and Nakao, Shinji},
  title = {Romiplostim with ciclosporin A in patients with aplastic anaemia naïve to immunosuppressive therapy: A phase 2/3 study},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.20206}
}
Kostenlos starten →